Sun Pharma, India’s largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma’s specialty portfolio, including UNLOXCYT, an FDA-approved treatment for advanced skin cancer, expanding its global presence in oncology treatments.
Sun Pharma, India’s largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma’s specialty portfolio, including UNLOXCYT, an FDA-approved treatment for advanced skin cancer, expanding its global presence in oncology treatments. Sun Pharma, India’s largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma’s specialty portfolio, including UNLOXCYT, an FDA-approved treatment for advanced skin cancer, expanding its global presence in oncology treatments. Read More
About The Author
